文献速递泌尿男性生殖肿瘤

LACOG 0415:阿比特龙联合ADT、阿帕他胺或两者联合治疗非去势睾酮水平晚期前列腺癌的2期随机试验

A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
PubMed 文献 · Eur J Cancer · 2021-10-13

LACOG 0415是一项2期开放标签非比较随机试验,纳入128例晚期去势敏感性前列腺癌(CSPC)患者,随机接受戈舍瑞林+阿比特龙+泼尼松(ADT+AAP)、阿帕他胺(APA)或阿帕他胺+阿比特龙+泼尼松(APA+AAP)。第25周PSA≤0.2 ng/mL的比例分别为75.6%、60.0%和79.5%。APA组未达到预期PSA应答率,但无ADT方案在晚期CSPC中显示出高PSA应答,值得进一步研究。

要点

  • 第25周PSA≤0.2 ng/mL比例:ADT+AAP组75.6%,APA组60.0%,APA+AAP组79.5%。
  • PSA下降≥80%比例分别为100%、90.0%和97.4%。
  • 3-4级不良事件发生率分别为31.0%、21.4%和36.4%。

核心结论

  • 无ADT方案在晚期CSPC中提供高PSA应答,但APA单药组未达到第25周PSA≤0.2 ng/mL的预期率。
  • 结果支持进一步研究无ADT治疗作为晚期CSPC的替代选择。

研究设计与样本

  • LACOG 0415是一项2期、开放标签、非比较、随机试验。
  • 128例晚期CSPC患者按1:1:1随机分配至ADT+AAP组、APA组或APA+AAP组。
  • 主要终点为改良意向治疗人群第25周PSA≤0.2 ng/mL的比例。

主要发现

  • 120例患者可评估第25周PSA应答;17.2%为高危生化复发,8.6%为局部晚期,74.2%为远处转移。
  • 第25周PSA≤0.2 ng/mL比例:ADT+AAP组75.6%(95%CI 59.7%-87.6%),APA组60.0%(95%CI 43.3%-75.1%),APA+AAP组79.5%(95%CI 63.5%-90.7%)。
  • PSA下降≥80%比例:ADT+AAP组100%,APA组90.0%,APA+AAP组97.4%。
  • 3-4级不良事件发生率:ADT+AAP组31.0%,APA组21.4%,APA+AAP组36.4%。
  • 睾酮水平在APA组显著升高,在ADT+AAP和APA+AAP组显著降低。

临床怎么用

  • 无ADT方案(阿帕他胺单药或联合阿比特龙+泼尼松)在晚期CSPC中显示高PSA应答,可作为进一步研究的替代策略。
  • APA单药方案未达到预设PSA应答率,需谨慎选择。

局限性

  • 本研究为2期、非比较设计,样本量有限。
  • 随访时间短,主要终点为第25周PSA应答,缺乏长期生存数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatments for advanced castration-sensitive prostate cancer (CSPC). We investigated ADT-free alternatives for advanced CSPC. PATIENTS AND METHODS: LACOG 0415 is a phase 2, open-label, non-comparative, randomized trial. Patients with advanced CSPC were randomized (1:1:1) to receive goserelin plus abiraterone acetate and prednisone (ADT plus AAP arm), apalutamide (APA arm), or apalutamide plus abiraterone acetate and prednisone (APA plus AAP arm). The primary endpoint was the proportion of patients with PSA of ≤0.2 ng/mL at week 25 in the modified intention-to-treat population. Safety analyses were performed in all patients with at least one dose of the study drug. RESULTS: Of 128 randomized patients, 120 patients were evaluable for PSA response at week 25; 17.2% had a high-risk biochemical recurrence, 8.6% had locally advanced disease, and 74.2% had distant metastases. At week 25, PSA of ≤0.2 ng/mL was observed in 75.6% (95%CI 59.7%-87.6%), 60.0% (95%CI 43.3%-75.1%), and 79.5% (95%CI 63.5%-90.7%) of patients in ADT plus AAP, APA, and APA plus AAP arms, respectively. PSA decline of ≥80% was observed in 100%, 90.0%, and 97.4%, respectively. Grade 3-4 AEs were observed in 31.0%, 21.4% and 36.4%, respectively. Testosterone levels increased significantly in the APA arm and decreased significantly in ADT plus AAP and APA plus AAP arms. CONCLUSIONS: ADT-free alternatives provide a high PSA response in advanced CSPC, although the APA arm did not reach the expected rate of PSA of ≤0.2 ng/mL at week 25. These results warrant further investigation of ADT-free treatments as alternatives in advanced CSPC. SOURCE STUDY REGISTRATION: ClinicalTrials.govNCT02867020.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Maluf FC, Schutz FA, Cronemberger EH, et al. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer. 2021. PMID: 34655838. doi:10.1016/j.ejca.2021.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。